Alzheimer's Disease and Dementia
Not the same thing as normal aging
Normal aging, mild cognitive impairment, and dementia are three different things, and Alzheimer's disease is one specific cause of dementia rather than another name for it. The distinctions are not academic: they change what a diagnosis means, what can be treated, and what to expect next.
The Distinction
One is the symptom, one is the cause
Two separate questions get collapsed into one. How much a person's thinking has changed is a different question from what is causing the change, and answering the first does not answer the second.
The symptom
A description of how much has changed
These are clinical diagnoses. They are based on what can be observed rather than on what is happening in the brain. Each one says how far thinking has moved from where it was and how much it is affecting someone day to day.
Normal age-related changes might be noticed and become frustrating, but on their own, they do not mean anything is wrong.
Mild cognitive impairment
Changes are measurable and greater than expected for a person's age, but daily life still works without help.
Dementia
Memory, thinking, or reasoning has declined far enough to interfere with daily life.
The cause
A disease, which the description does not name
None of those labels says what is behind the change. Several different diseases can produce the same picture, each with its own biology and its own course. Alzheimer's disease is the most common of them, and it is not the only one.
The same degree of impairment can come from different diseases, or from more than one at the same time. A disease process can also be under way in the brain for years before, or without, any of those changes appearing at all.
In the Brain
What Alzheimer's disease does
Three physical changes, unfolding slowly and largely silently, long before anyone notices a symptom.
Amyloid plaques
A protein called amyloid-beta clumps together in the spaces between brain cells. It is the earliest of the three changes to appear, and it accumulates for years without producing any symptom.
Tau tangles
Inside neurons, a protein called tau twists into tangles and disrupts the internal transport a cell depends on. How severe someone's thinking problems are tracks the burden of tangles more closely than it tracks plaques.
Loss of connections
Neurons lose the synapses that link them, and then the cells themselves are lost. Inflammation in the brain's immune cells accompanies the process and may accelerate it.
That long silent window is also an opportunity. Much of this biology can now be read from a single blood sample, accurately enough that the tests have been evaluated for use in primary care. That is what makes it possible to study resilience while people are still well.
Different Paths
How much disease is not the same as how much it shows
The changes in the brain unfold across more than two decades, and they do so largely on their own schedule. Whether they lead to observable symptoms, and when, is a separate question. The two track each other loosely enough that neither one reliably predicts the other.
Symptoms with little disease
Thinking can decline while relatively little Alzheimer's pathology is present. Something else is usually contributing, which is one of the reasons an evaluation is worth having rather than an assumption.
Disease with no symptoms
Among people who died with no cognitive impairment at all, more than a third turned out to meet the pathological criteria for Alzheimer's disease. Their overall thinking scores were much the same as everyone else's, separated only by a subtle difference on tests of memory.
The gap between disease and symptoms is where resilience lives
People who carry the biology and keep their thinking are the clearest evidence there is that brain changes do not settle the outcome on their own. Something is protecting them. What that something is, how much of it is inherited, and how much of it anyone can build are open questions, and answering them takes following enough people closely enough, for long enough, to see what separates them.
Getting Evaluated
The appearance of symptoms warrants more investigation
Mild cognitive impairment is where changes in thinking first become measurable, and it is the stretch of the trajectory where an evaluation earns the most. Treatable causes are still treatable, the risk factors that shape the years ahead still have room to act on, and it is the window most prevention research is built around.
It can progress
Between 5% and 10% of people with mild cognitive impairment develop dementia in a given year, most often Alzheimer's disease.
It can hold steady
Most people with mild cognitive impairment do not go on to develop dementia, even after ten years of follow up.
It can improve
Across 25 studies that followed people over time, an estimated 18% returned to normal cognition. Among studies drawn from the general population rather than memory clinics, about 25% did.
Waiting removes options rather than preserving them
Many people wait, because a diagnosis feels like something that cannot be undone.
What an evaluation usually involves
- A history of what has changed, ideally with someone who knows the person well
- Pencil-and-paper or computerized thinking and memory tests
- Bloodwork to check for treatable causes such as thyroid problems or vitamin deficiencies
- Brain imaging, and in some cases biomarker testing, when the picture is unclear
A primary care provider is the right place to start. Poor sleep, depression, medication side effects, thyroid problems, vitamin deficiencies, and excess alcohol use can all interfere with thinking and memory, and symptoms often improve once the cause is treated. A provider can address those directly and refer on to a memory specialist when that is the right next step.